We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-5.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.54B
AUM Growth
-$303M
Cap. Flow
-$71.8M
Cap. Flow %
-2.82%
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
27
Reduced
36
Closed
3

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14M
2
ISRG icon
Intuitive Surgical
ISRG
+$11.4M
3
BSX icon
Boston Scientific
BSX
+$9.19M
4
AZN icon
AstraZeneca
AZN
+$8.8M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.52M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.5M
2
MCK icon
McKesson
MCK
+$14.5M
3
MDT icon
Medtronic
MDT
+$11M
4
LLY icon
Eli Lilly
LLY
+$10.6M
5
ILMN icon
Illumina
ILMN
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
2 Real Estate 3.13%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
51
BioNTech
BNTX
$23.5B
$14.2M 0.56%
95,042
– –
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$14.1M 0.55%
312,192
+116,372
+59% +$5.31M
ITCI
53
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.9M 0.55%
243,437
-47,499
-16% -$2.69M
VTR icon
54
Ventas
VTR
$44.7B
$12.8M 0.5%
248,131
– –
NVS icon
55
Novartis
NVS
$301B
$11.5M 0.45%
136,225
– –
CVS icon
56
CVS Health
CVS
$134B
$11.5M 0.45%
123,803
-23,650
-16% -$2.31M
BMRN icon
57
BioMarin Pharmaceuticals
BMRN
$11.7B
$10.6M 0.42%
128,004
– –
LH icon
58
Labcorp
LH
$25.9B
$10.3M 0.41%
51,381
– –
CRL icon
59
Charles River Laboratories
CRL
$11.3B
$10.2M 0.4%
47,894
-14,096
-23% -$3.44M
BHVN
60
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.2M 0.4%
70,176
– –
KRTX
61
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$10M 0.39%
79,057
-21,401
-21% -$2.46M
QURE icon
62
uniQure
QURE
$2.93B
$9.72M 0.38%
521,693
– –
DXCM icon
63
DexCom
DXCM
$28.8B
$9.68M 0.38%
129,884
-16,800
-11% -$1.53M
ACH
64
Accendra Health
ACH
$256M
$9.06M 0.36%
288,167
– –
DOC
65
DELISTED
PHYSICIANS REALTY TRUST
DOC
$8.65M 0.34%
495,733
– –
OHI icon
66
Omega Healthcare
OHI
$15B
$8.64M 0.34%
306,433
– –
LNTH icon
67
Lantheus
LNTH
$6.58B
$8.39M 0.33%
+127,092
New +$8.01M
ONC
68
BeOne Medicines Ltd
ONC
$33.4B
$8.26M 0.32%
51,018
– –
SBRA icon
69
Sabra Healthcare REIT
SBRA
$5.38B
$7.13M 0.28%
510,660
– –
HQY icon
70
HealthEquity
HQY
$8.44B
$7.08M 0.28%
115,314
+12,000
+12% +$769K
ELV icon
71
Elevance Health
ELV
$81.6B
$7.07M 0.28%
14,644
– –
LTC
72
LTC Properties
LTC
$2.06B
$7M 0.28%
182,293
– –
ADUS icon
73
Addus HomeCare
ADUS
$2.18B
$6.96M 0.27%
83,632
– –
AMN icon
74
AMN Healthcare
AMN
$1.35B
$6.71M 0.26%
61,201
– –
DNLI icon
75
Denali Therapeutics
DNLI
$3.86B
$6.55M 0.26%
222,420
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Tekla Capital Management held 180 positions worth $2.54B, down 11% from $2.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 4.4%. Tekla Capital Management opened 5 new positions and exited 3, leaving the 180-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2022 buy was Lantheus: 127,092 shares worth $8.39M.
  • Tekla Capital Management added most to Vertex Pharmaceuticals in Q2 2022, an estimated $14M increase.
  • Tekla Capital Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $19.5M.
  • Tekla Capital Management fully exited Revvity in Q2 2022, selling an estimated $5.83M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2022.
  • Tekla Capital Management opened 5 new positions and closed 3 in Q2 2022.
  • Tekla Capital Management's portfolio value fell 11% quarter-over-quarter to $2.54B.

Based on Tekla Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.